Supriya Lifescience (NSE:SUPRIYA) Current Deferred Revenue: ₹ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUPRIYA Supriya Lifescience Ltd NSE:SUPRIYA
81 GF Score
Price ₹957.70
GF Value ₹876.66
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Supriya Lifescience Current Deferred Revenue?

Supriya Lifescience NSE:SUPRIYA +0.63% 81 Current Deferred Revenue is ₹ Mil as of Jun. 2026. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 81/100 and a GF Value™ of ₹876.66 (Fairly Valued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Supriya Lifescience's current deferred revenue for the quarter that ended in Jun. 2026 was ₹ Mil.

Supriya Lifescience Current Deferred Revenue Related Terms

Supriya Lifescience Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Supriya Lifescience's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supriya Lifescience Current Deferred Revenue Chart

Supriya Lifescience Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 178.31 55.09 148.68 43.55 31.44

Supriya Lifescience Quarterly Data
Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 31.44 -
NSE:SUPRIYA
81GF Score
Supriya Lifescience Ltd NSE:SUPRIYA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹ Mil mean?
Supriya Lifescience (NSE:SUPRIYA) has a Current Deferred Revenue of ₹ Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Supriya Lifescience and its competitors.
Is Supriya Lifescience's Current Deferred Revenue too high?
Supriya Lifescience's current Current Deferred Revenue is ₹ Mil. Overall, Supriya Lifescience has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Current Deferred Revenue compare to VRTX and REGN?
Supriya Lifescience's Current Deferred Revenue of ₹ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current Current Deferred Revenue is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Fairly Valued. The stock's GF Value™ is ₹876.66, compared to a current price of ₹957.70 — trading 9.2% above its estimated fair value. The current Current Deferred Revenue is ₹ Mil. Supriya Lifescience's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Current Deferred Revenue is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?

Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued. The current stock price of ₹957.70 is trading 9.2% above its estimated GF Value™ of ₹876.66. GuruFocus considers Supriya Lifescience to be Fairly Valued.

Key valuation signals for NSE:SUPRIYA:

  • Current Deferred Revenue: ₹ Mil
  • GF Value™: ₹876.66 vs. price of ₹957.70 (9.2% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supriya Lifescience Business Description

Other Exchanges 543434:India
Address Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is an Indian manufacturer of active pharmaceutical ingredients (APIs) and finished dosage formulations, based in Maharashtra with manufacturing facilities at Lote Parshuram and Ambernath. The company produces a portfolio of niche APIs across therapeutic categories including anaesthetics, analgesics, antihistamines, anti-asthmatics, anti-allergics, antihypertensives, and vitamins, and also offers contract development and manufacturing (CDMO) services and finished formulations. Its customers are primarily pharmaceutical companies and formulators in regulated and semi-regulated markets. Supriya Lifescience exports to more than 80 countries, with Europe accounting for the largest share of revenue, followed by Asia, North America, Latin America, and other regions. Revenue is generated mainly through the sale of APIs and formulations, supplemented by CDMO arrangements. The company invests in research and development to expand its product pipeline and add new molecules.
81GF Score

Get the complete analysis for NSE:SUPRIYA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹957.70
Price
₹876.66
GF Value